You are here

Our science / Clinical Trials / Find a Trial / NCT00467766

Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer’s Disease

Back to Search Print Save as PDF Bookmark Trial

NCT00467766

Last updated on February 23, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Aging and Dementia Research Center, Silberstein Institute, NYU School of Medicine
New York, New York, 10016 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer Disease, Caregivers
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
21 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Individuals diagnosed with mild to moderate stage Alzheimer’s disease and their spouse
caregivers

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Severe psychological or physical illness

- Unwillingness by either spouse to participate in all aspects of the study

NCT00467766
Pfizer
Completed
Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer’s Disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

Based on your search, you may also be interested in

Alzheimer Disease
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SAM-531 in Healthy Subjects
NCT00479700
All Genders
Alzheimer Disease
Study Evaluating Potential Pharmacokinetic (PK) Interaction Between Lecozotan and Digoxin
NCT00563732
All Genders
Alzheimer Disease
Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients
NCT00676143
All Genders
50+
Years
Multiple Sites
Alzheimer Disease
Study Evaluating the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAM-315 in Healthy Adults
NCT00479440
All Genders

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now